NO20074913L - Enhetsdoseringsformer av temozolomid - Google Patents

Enhetsdoseringsformer av temozolomid

Info

Publication number
NO20074913L
NO20074913L NO20074913A NO20074913A NO20074913L NO 20074913 L NO20074913 L NO 20074913L NO 20074913 A NO20074913 A NO 20074913A NO 20074913 A NO20074913 A NO 20074913A NO 20074913 L NO20074913 L NO 20074913L
Authority
NO
Norway
Prior art keywords
dosage forms
unit dosage
temozolomide
relates
patient
Prior art date
Application number
NO20074913A
Other languages
English (en)
Inventor
Jacqueline Rose Bersch
Mark Manzo
Sumant Ramachandra
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20074913L publication Critical patent/NO20074913L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Denne oppfinnelsen vedrører enhetsdoseringsformer av temozolomid. Disse enhetsdoseringsformene er spesielt velegnet for reduksjon av pillebelastningen og forbedring av pasientaksept. Oppfinnelsen vedrører også fremgangsmåter for å behandle proliferative forstyrrelser hos en pasient med disse enhetsdoseringsformene. Oppfinnelsen vedrører i tillegg sett som omfatter disse doseringsformene.
NO20074913A 2006-06-26 2007-09-27 Enhetsdoseringsformer av temozolomid NO20074913L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26
PCT/US2007/014761 WO2008002544A2 (en) 2006-06-26 2007-06-25 Unit dosage forms of temozolomide

Publications (1)

Publication Number Publication Date
NO20074913L true NO20074913L (no) 2009-03-26

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074913A NO20074913L (no) 2006-06-26 2007-09-27 Enhetsdoseringsformer av temozolomid

Country Status (13)

Country Link
EP (1) EP1901740A2 (no)
JP (1) JP2008534692A (no)
KR (2) KR20100055543A (no)
CN (1) CN101309686A (no)
AR (1) AR061618A1 (no)
AU (1) AU2007221979A1 (no)
BR (1) BRPI0702847A (no)
CA (1) CA2610439A1 (no)
CL (1) CL2007001864A1 (no)
NO (1) NO20074913L (no)
TW (1) TWI326598B (no)
WO (1) WO2008002544A2 (no)
ZA (1) ZA200708280B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
EP3432901B1 (en) * 2016-03-21 2021-09-01 Duke University Sequential anti-cancer treatment
WO2018167627A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE310515T1 (de) * 1999-03-30 2005-12-15 Schering Corp Verbesserte krebsbehandlung mit temozolomid
CA2585446A1 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level

Also Published As

Publication number Publication date
CN101309686A (zh) 2008-11-19
AU2007221979A9 (en) 2008-01-10
AU2007221979A1 (en) 2008-01-10
WO2008002544A2 (en) 2008-01-03
TWI326598B (en) 2010-07-01
ZA200708280B (en) 2009-03-25
EP1901740A2 (en) 2008-03-26
AR061618A1 (es) 2008-09-10
CL2007001864A1 (es) 2008-02-08
CA2610439A1 (en) 2007-12-26
BRPI0702847A (pt) 2008-04-01
WO2008002544A3 (en) 2008-02-07
JP2008534692A (ja) 2008-08-28
KR20100055543A (ko) 2010-05-26
TW200808803A (en) 2008-02-16
KR20080015777A (ko) 2008-02-20

Similar Documents

Publication Publication Date Title
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
NO20084341L (no) Anvendelse av DPP-IV inhibitorer
NZ609280A (en) Method for treatment of constipation-predominant irritable bowel syndrome
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX350046B (es) Tratamientos para trastornos gastrointestinales.
MX2010006823A (es) Metodos para el tratamiento de la gota.
NZ592786A (en) Methods and compositions for treating complement-associated disorders using eculizumab
ZA201001193B (en) 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders
NO20074130L (no) Behandlingsfremgangsmate
TN2015000027A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
MY161656A (en) Therapeutic use of diaminophenothiazines
PT2073811E (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
WO2007058990A3 (en) Therapy using cytokine inhibitors
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
NZ608813A (en) Treatment of myocardial infarction using tgf - beta antagonists
MX2009004134A (es) Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
TW200631584A (en) A medicament related to mirtazapine for the treatment of hot flush
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
TN2009000136A1 (en) Sequential combination therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application